9:13 AM
 | 
Mar 16, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Omeros reports Phase II OS data for OMS721 in thrombotic microangiopathy

Omeros Corp. (NASDAQ:OMER) reported data from 18 patients with hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (HCT-TMA) in a Phase II trial and one HCT-TMA patient treated under a compassionate use program showing that once-weekly OMS721 for...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >